Home > Healthcare > Pharmaceuticals > Finished Drug Form > albumin market
Get a free sample of Albumin Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Albumin Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Human serum albumin market held 82.6% revenue share in 2023 and is set to gain traction by 2032, attributed to its extensive therapeutic applications, biocompatibility, and safety profile.
The market size of albumin was reached USD 5.6 billion in 2023 and is set to register 6.5% CAGR from 2024 to 2032, driven by an increasing prevalence of chronic diseases and growing non-therapeutic applications of albumin.
North America albumin market is anticipated to reach USD 3.9 billion by the end of 2032, attributed to its advanced healthcare infrastructure, thriving pharmaceutical industry, high prevalence of chronic diseases, and stringent regulatory environment.
Albumedix Ltd, Akron Biotech, Baxter International Inc., Bristol-Myers Squibb Company, China Biologic Products Holdings Inc., CSL Behring LLC, Grifols (Biotest AG), Merck & Co., Inc., Octapharma AG are some of the major industry contenders.